double homeobox 4 like 52 (pseudogene)Genealiases: []
Q-omics provides the consensus-scored DUX4L52 profile across patient tissues and cancer cell-line models. DUX4L52 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, DUX4L52 is differentially expressed in 3, with the highest sampling consensus in PRAD. Additionally, DUX4L52 RNA expression shows 6,196 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight SKCM, PRAD, and COAD as cancer lineages where DUX4L52 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DUX4L52 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DUX4L52 survival associations across molecular data types. DUX4L52 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DUX4L52 RNA expression–survival associations across cancer types. High DUX4L52 expression shows unfavorable associations in SKCM, PRAD, SARC, CESC, LIHC and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for DUX4L52 RNA expression.
This table summarizes DUX4L52 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for DUX4L52. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DUX4L52 shows lower tumor expression in PRAD and higher tumor expression in BRCA and THCA. The PRAD box plot shows higher DUX4L52 RNA expression in normal versus tumor tissue (log2 FC = −0.022, t-test p = .027).
This table shows molecular features associated with DUX4L52 in patient tissues and cancer cell lines. In patient samples, DUX4L52 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
